Abstract
We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl] -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.
| Original language | English |
|---|---|
| Pages (from-to) | 122-128 |
| Number of pages | 7 |
| Journal | International Journal of Impotence Research |
| Volume | 21 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2009 Mar 9 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Urology
Cite this
}
Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS. / Chung, Byungha; Lee, J. Y.; Lee, S. H.; Yoo, S. J.; Lee, S. W.; Oh, C. Y.
In: International Journal of Impotence Research, Vol. 21, No. 2, 09.03.2009, p. 122-128.Research output: Contribution to journal › Article
TY - JOUR
T1 - Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS
AU - Chung, Byungha
AU - Lee, J. Y.
AU - Lee, S. H.
AU - Yoo, S. J.
AU - Lee, S. W.
AU - Oh, C. Y.
PY - 2009/3/9
Y1 - 2009/3/9
N2 - We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl] -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.
AB - We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl] -1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.
UR - http://www.scopus.com/inward/record.url?scp=62449215028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62449215028&partnerID=8YFLogxK
U2 - 10.1038/ijir.2009.2
DO - 10.1038/ijir.2009.2
M3 - Article
VL - 21
SP - 122
EP - 128
JO - International Journal of Impotence Research
JF - International Journal of Impotence Research
SN - 0955-9930
IS - 2
ER -